Navigation Links
Vaccinogen Names Veteran Biotech Executive Michael Kranda President & CEO
Date:9/30/2010

FREDERICK, Md., Sept. 30 /PRNewswire/ -- Vaccinogen, Inc. has appointed veteran biotechnology executive Michael L. Kranda as President and Chief Executive Officer to guide it through its next stage of growth.

"The timing couldn't be better – as the company proceeds to finance and launch our pivotal Phase III clinical trial," said Michael G. Hanna, Jr., Ph.D., Vaccinogen's Founder & Chairman and inventor of the company's unique cancer-fighting vaccine OncoVAX®.

Co-founder and COO Andrew L. Tussing said Mr. Kranda was the clear choice to head the break-through biopharmaceutical company.  "He has the vision and experience to lead us through this important phase in our growth," Mr. Tussing said.

"I'm excited about OncoVAX®'s potential to save lives and Vaccinogen's role as a pioneer in using autologous vaccines to combat cancer," said Mr. Kranda.  "I look forward to building on the OncoVAX® technology to create an important and leading company in the cancer vaccine arena."

Literally Turning Cancer on Itself™, Vaccinogen works to harness the body's immune system to prevent the recurrence of cancer in patients recovering from the disease.

Mr. Kranda brings to Vaccinogen more than two decades of experience developing biotechnology platforms, products and companies. He sits on the board of directors of several companies including PTC Therapeutics.

Previously, Mr. Kranda served as the CEO, President and Director of Anesiva. Prior to joining Anesiva, Mr. Kranda was Managing Director of Vulcan Capital, Paul Allen's investment arm, where he led the life science venture investments team.  Mr. Kranda also served as CEO of Oxford GlycoSciences, and led their listings on the LSE and NASDAQ exchanges and prior to that was President and COO of Immunex (now Amgen).

Mr. Kranda holds a BA and an MBA from the University of Washington School of Business.

About OncoVAX®OncoVAX® transforms the body's immune response to prevent the return of the disease after surgery. As published in the journal Human Vaccines, Stage II OncoVAX® patients achieve "a 57.1% relative risk reduction in the recurrence of colon cancer" vs. the control patients in a previous clinical trial.

About VaccinogenVaccinogen develops and commercializes cancer vaccines and other immunotherapeutic products – Turning Cancer on Itself™. Based in Frederick, MD, the Company has a portfolio of product candidates for the treatment of cancer in various stages of clinical development.

www.vaccinogeninc.comContact:Andrew L. TussingVaccinogenatussing@vaccinogeninc.com301-668-8400
'/>"/>

SOURCE Vaccinogen, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. RF Technologies® Names Mark Harwood New President
2. FierceBiotech Names iPierian as One of the Fierce 15 Biotech Companies of 2010
3. DNASequencing.com and a Portfolio of 318 Genetic Domain Names to be Auctioned Off at Epik.com Domain Development Conference
4. Fibrocell Science, Inc. Names Biotechnology and Genetic Research Expert Stefan Gruenwald, M.D., Ph.D., to Scientific Advisory Board
5. Protalix BioTherapeutics Names Tzvi Palash Chief Operating Officer
6. Signum Biosciences Names Braham Shroot as Chief Executive Officer
7. Diversity Publication Names University Hospitals One of Top Hospital Systems in the Nation
8. Talecris Names John Perkins as Executive Vice President, Global Commercial Operations
9. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
10. Transgenomic Names Dr. Katherine Richardson Technical Director for Laboratory Services
11. Thomson Reuters Names the Worlds Hottest Researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... NC (PRWEB) , ... June 24, 2016 , ... Researchers ... the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are ... to read it now. , Diagnostic biomarkers are signposts in the blood, lung ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking ... Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity as ...
Breaking Biology Technology:
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting ... are setting a new clinical standard in telehealth thanks ... By leveraging the higi platform, IMPOWER patients can routinely ... pulse and body mass index, and, when they opt ... and convenient visit to a local retail location at ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
Breaking Biology News(10 mins):